Trial Profile
Treatment of Severe Steroid-refractory Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Apr 2016
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary) ; Etanercept (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 20 Jan 2016 Status changed from recruiting to completed.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 22 Jan 2013 New trial record